Literature DB >> 21640483

Impact of venous tumour thrombus consistency (solid vs friable) on cancer-specific survival in patients with renal cell carcinoma.

Roberto Bertini1, Marco Roscigno, Massimo Freschi, Elena Strada, Diego Angiolilli, Giovanni Petralia, Rayan Matloob, Francesco Sozzi, Umberto Capitanio, Luigi Filippo Da Pozzo, Renzo Colombo, Giorgio Guazzoni, Anna Cremonini, Francesco Montorsi, Patrizio Rigatti.   

Abstract

BACKGROUND: To our knowledge, the impact of venous tumour thrombus (VTT) consistency in patients affected by renal cell carcinoma (RCC) has never been addressed.
OBJECTIVE: To analyse the effect of VTT consistency on cancer-specific survival (CSS). DESIGN, SETTING, AND PARTICIPANTS: We retrospectively analysed 174 consecutive patients with RCC and renal vein or inferior vena cava (IVC) VTT who underwent surgical treatment between 1989 and 2007 at our institute. INTERVENTION: All patients underwent radical nephrectomy and thrombectomy. MEASUREMENTS: Pathologic specimens were reviewed by a single uropathologist. In addition to traditional pathologic features, the morphologic aspect of the tumour thrombus was evaluated to distinguish solid from friable patterns. The prognostic role of thrombus consistency (solid vs friable) on CSS was assessed by means of Cox regression models. RESULTS AND LIMITATIONS: The VTT was solid in 107 patients (61.5%) and friable in 67 patients (38.5%). The presence of a friable VTT increased the risk of having synchronous nodal or distant metastases, higher tumour grade, higher pathologic stage, and simultaneous perinephric fat invasion (all p < 0.05). The median follow-up was 24 mo. The median CSS was 33 mo; the median CSS was 8 mo in patients with a friable VTT and 55 mo in patients with a solid VTT (p < 0.001). On multivariable analyses, the presence of a friable VTT was an independent predictor of CSS (p = 0.02). The power of our conclusion may be somewhat limited by the relatively small study population and the retrospective nature of the study.
CONCLUSIONS: In patients with RCC and VTT, the presence of a friable thrombus is an independent predictor of CSS. If our finding is confirmed by further studies, the consistency of the tumour thrombus should be introduced into routine pathologic reports to provide better patient risk stratification.
Copyright © 2011 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21640483     DOI: 10.1016/j.eururo.2011.05.029

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  8 in total

1.  Fate of newly developed pulmonary embolism after surgery for renal cell carcinoma with vena cava thrombus.

Authors:  Sangjun Yoo; Sang Hoon Song; Heounjeong Go; Dalsan You; Cheryn Song; Jun Hyuk Hong; Choung-Soo Kim; Hanjong Ahn; In Gab Jeong
Journal:  Int Urol Nephrol       Date:  2017-04-11       Impact factor: 2.370

2.  Surgical resection of recurrent inferior vena cava tumor following radical nephrectomy for renal cell carcinoma: A case report.

Authors:  Guangyuan Li; Zhiqiang Zhang; Dongdong Xie; Nan Ye; Dexin Yu
Journal:  Oncol Lett       Date:  2015-05-06       Impact factor: 2.967

3.  Kidney cancer: Incorporating new parameters into pathological staging of RCC.

Authors:  Katrina Ray
Journal:  Nat Rev Urol       Date:  2011-07-08       Impact factor: 14.432

4.  Renal cell carcinoma and tumour thrombus in the inferior vena cava: clinical outcome of 98 consecutive patients and the prognostic value of preoperative parameters.

Authors:  Christian Niedworok; Bettina Dörrenhaus; Frank Vom Dorp; Jarowit Adam Piotrowski; Stephan Tschirdewahn; Tibor Szarvas; Herbert Rübben; Marcus Schenck
Journal:  World J Urol       Date:  2014-11-30       Impact factor: 4.226

5.  Does left side renal cell carcinoma (RCC) with renal vein/vena cava thrombus predict worse prognosis than equivalent right side RCC tumor thrombus?

Authors:  David D Thiel; Christine M Lohse; Michelle L Arnold; John C Cheville; Bradley C Leibovich; Alexander S Parker
Journal:  Int Urol Nephrol       Date:  2012-04-13       Impact factor: 2.370

6.  Renal cell carcinoma with inferior vena cava involvement: Prognostic effect of tumor thrombus consistency on cancer specific survival.

Authors:  Rene Mager; Siamak Daneshmand; Christopher P Evans; Joan Palou; Juan I Martínez-Salamanca; Viraj A Master; James M McKiernan; John A Libertino; Axel Haferkamp; Axel Haferkamp; Umberto Capitanio; Joaquín A Carballido; Venancio Chantada; Thomas Chromecki; Gaetano Ciancio; Siamak Daneshmand; Christopher P Evans; Paolo Gontero; Javier González; Markus Hohenfellner; William C Huang; Theresa M Koppie; John A Libertino; Estefanía Linares Espinós; Adam Lorentz; Juan I Martínez-Salamanca; Viraj A Master; James M McKiernan; Francesco Montorsi; Giacomo Novara; Padraic O'Malley; Sascha Pahernik; Joan Palou; José Luis Pontones Moreno; Raj S Pruthi; Oscar Rodriguez Faba; Paul Russo; Douglas S Scherr; Shahrokh F Shariat; Martin Spahn; Carlo Terrone; Derya Tilki; Dario Vázquez-Martul; Cesar Vera Donoso; Daniel Vergho; Eric M Wallen; Richard Zigeuner
Journal:  J Surg Oncol       Date:  2016-08-26       Impact factor: 3.454

7.  The Prognostic Impact of a Positive Vascular Margin on pT3 Clear Cell Renal Cell Carcinoma.

Authors:  Nick W Liu; James D Wren; Emily Vertosick; Justin K Lee; Nicholas E Power; Nicole E Benfante; Simon Y Kimm; Manjit S Bains; Daniel D Sjoberg; Paul Russo; Jonathan A Coleman
Journal:  J Urol       Date:  2015-09-10       Impact factor: 7.450

8.  Genomic features of renal cell carcinoma with venous tumor thrombus.

Authors:  Gregor Warsow; Daniel Hübschmann; Kortine Kleinheinz; Cathleen Nientiedt; Martina Heller; Laura Van Coile; Yanis Tolstov; Lukas Trennheuser; Kathrin Wieczorek; Carine Pecqueux; Claudia Gasch; Timur Kuru; Joanne Nyarangi-Dix; Gencay Hatiboglu; Dogu Teber; Sven Perner; Albrecht Stenzinger; Wilfried Roth; Boris Hadaschik; Sascha Pahernik; Dirk Jäger; Carsten Grüllich; Anette Duensing; Roland Eils; Matthias Schlesner; Holger Sültmann; Markus Hohenfellner; Stefan Duensing
Journal:  Sci Rep       Date:  2018-05-10       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.